# Insmed (INSM) — Earnings

INSM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/insm/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.06 |
| EPS estimate | −$0.69 |
| EPS surprise | +91.35% |
| Revenue surprise | +8.06% |
| Revenue | $425.5M |
| Revenue estimate | $393.7M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1104506/000110450626000041/insm-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/6c53a8ca-1413-ac0c-6828-97de615e4441.html) |

Insmed reported Q2 2026 results on August 6, 2026. The company posted a loss of $0.06 per share, far narrower than the expected loss of $0.69, a 91.35% beat. Revenue reached $425.5 million, above the $393.7 million estimate by about 8%. A year earlier, in Q2 2025, the loss was $1.70 per share and revenue $107.4 million, so revenue nearly quadrupled.

Every quarter in the table is a loss. The annual loss widened from $3.90 per share in 2022 to $5.34 in 2023, $5.59 in 2024 and $6.41 in 2025. The trend has since turned: the quarterly loss shrank from $1.75 in Q3 2025 to $1.54, $0.76 and now $0.06. Revenue rose in each of the last five quarters. Annual revenue grew from $245.3 million in 2022 to $606.3 million in 2025, a jump of about 67% in the last year. Insmed beat the EPS estimate in 6 of the last 20 quarters, including the two most recent.

Third-quarter results came between October 26 and October 31 in each of the past five years. That points to late October 2026 for the next report.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$0.69 | −$0.06 | 91.35% | $393.7M | $425.5M |
| Q1 2026 | May 7, 2026 | −$0.96 | −$0.76 | 21.11% | $300.8M | $306.0M |
| Q4 2025 | Feb 19, 2026 | −$1.07 | −$1.54 | -43.74% | $231.2M | $263.8M |
| Q3 2025 | Oct 30, 2025 | −$1.33 | −$1.75 | -31.72% | $115.4M | $142.3M |
| Q2 2025 | Aug 7, 2025 | −$1.30 | −$1.70 | -30.84% | $104.1M | $107.4M |
| Q1 2025 | May 8, 2025 | −$1.34 | −$1.42 | -6.18% | $91.5M | $92.8M |
| Q4 2024 | Feb 20, 2025 | −$1.17 | −$1.32 | -12.74% | $102.1M | $104.4M |
| Q3 2024 | Oct 31, 2024 | −$1.20 | −$1.27 | -5.65% | $93.4M | $93.4M |
| Q2 2024 | Aug 8, 2024 | −$1.24 | −$1.94 | -55.90% | $88.0M | $90.3M |
| Q1 2024 | May 9, 2024 | −$1.24 | −$1.06 | 14.36% | $77.8M | $75.5M |
| Q4 2023 | Feb 22, 2024 | −$1.15 | −$1.28 | -11.01% | $81.9M | $83.7M |
| Q3 2023 | Oct 26, 2023 | −$1.14 | −$1.11 | 2.73% | $79.1M | $79.1M |
| Q2 2023 | Aug 3, 2023 | −$1.13 | −$1.78 | -56.99% | $70.2M | $77.2M |
| Q1 2023 | May 4, 2023 | −$1.13 | −$1.17 | -3.75% | $64.2M | $65.2M |
| Q4 2022 | Feb 23, 2023 | −$1.05 | −$1.21 | -15.62% | $62.1M | $59.3M |
| Q3 2022 | Oct 27, 2022 | −$0.88 | −$1.09 | -24.06% | $66.9M | $67.7M |
| Q2 2022 | Aug 4, 2022 | −$0.89 | −$0.80 | 9.82% | $58.8M | $65.2M |
| Q1 2022 | May 5, 2022 | −$0.88 | −$0.80 | 9.30% | $53.3M | $53.1M |
| Q4 2021 | Feb 17, 2022 | −$0.90 | −$0.95 | -5.59% | $50.3M | $56.1M |
| Q3 2021 | Oct 28, 2021 | −$0.86 | −$0.96 | -11.85% | $48.2M | $46.8M |

## Frequently Asked Questions

### When did Insmed (INSM) last report earnings?

Insmed last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did INSM beat earnings estimates?

Yes. Insmed reported EPS of −$0.06 for Q2 2026 against a −$0.69 estimate — a 91.35% beat.

### How much revenue did INSM report last quarter?

Insmed reported $425.5M in revenue for Q2 2026, against a consensus estimate of $393.7M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).